{
    "pmcid": "8837488",
    "qa_pairs": {
        "How were the scFv antibodies engineered to form functional antigen-binding domains?": [
            "By linking the variable heavy (VH) and light (VL) chains with a flexible peptide linker",
            "By attaching the Fc region to the variable heavy (VH) chain",
            "By fusing the variable light (VL) chain directly to the constant region",
            "By using a rigid peptide linker between the heavy and light chains"
        ],
        "What is the primary target for the neutralizing antibodies developed in the study?": [
            "The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein",
            "The nucleocapsid protein of SARS-CoV-2",
            "The membrane protein of SARS-CoV-2",
            "The envelope protein of SARS-CoV-2"
        ],
        "What method was used to select scFv antibodies from phage display libraries?": [
            "Using the spike RBD as the target",
            "Using the nucleocapsid protein as the target",
            "Using the membrane protein as the target",
            "Using the envelope protein as the target"
        ],
        "What was the outcome of intranasal administration of scFv antibodies in animal models?": [
            "Effective prevention of infection",
            "Increased viral load",
            "No effect on viral transmission",
            "Induced severe immune response"
        ],
        "Which residues were identified as critical for ACE2 binding in the epitope recognized by 76clAbs?": [
            "F456, Y473, N487, and Y489",
            "A123, B456, C789, and D012",
            "G234, H567, I890, and J123",
            "K345, L678, M901, and N234"
        ]
    }
}